Shattuck Labs Inc
STTK
Get informed when a big investor buys or sells
+ FollowMarket Cap$543.14M
Close$
$0.47
92.2% downside
Current Fair Value
92.2% downsideOvervalued by 92.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $543.14 Million |
|---|---|
| Enterprise Value | $482.51 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.7 |
| Beta | 1.1 |
| Outstanding Shares | 129,779,297 |
Return
| Return on Equity | -24.90% |
|---|---|
| Return on Assets | -23.82% |
| Return on Invested Capital | -25.69% |
Valuation & Multiples
| P/E Ratio | -11.78 |
|---|---|
| PEG | -54.49 |
| Price to Sales | - |
| Price to Book Ratio | 6.07 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.82 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3783▲ 37.83% |
|---|---|
| Total Calls | 569,900▲ Infinity% |
| Total Puts | 215,600▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 64.70%▲ 14.74% |
|---|---|
| Total Invested | $582.66M▲ 61.65% |
| Investors Holding | 107▲ 24.00% |
ESG Score
No data
About Shattuck Labs Inc
59 employeesShattuck Labs, Inc. operates as a clinical-stage biotechnology company . The Company focuses on developing a novel class of biologic medicines for the treatment of cancer and autoimmune diseases. Shattuck Labs serves customers in the State of Texas.